Provided by Tiger Trade Technology Pte. Ltd.

Capricor Therapeutics

8.10
+0.35004.52%
Pre-market: 8.01-0.0900-1.11%07:01 EDT
Volume:2.89M
Turnover:22.93M
Market Cap:470.93M
PE:-3.28
High:8.27
Open:7.59
Low:7.46
Close:7.75
52wk High:40.37
52wk Low:2.96
Shares:58.14M
Float Shares:42.60M
Volume Ratio:0.39
T/O Rate:6.77%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4659
EPS(LYR):-2.2601
ROE:-73.70%
ROA:-33.63%
PB:1.91
PE(LYR):-3.58

Loading ...

Capricor: FDA committee voted evidence did not support Deramiocel effectiveness

TIPRANKS
·
Jul 30

Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel

THOMSON REUTERS
·
Jul 30

Capricor Therapeutics - Targets August 22, 2026 Pdufa Date for Deramiocel FDA Decision

THOMSON REUTERS
·
Jul 30

Capricor Therapeutics Inc : Maxim Group Cuts to Hold from Buy

THOMSON REUTERS
·
Jul 30

Capricor Therapeutics Inc. : Oppenheimer Cuts to Perform from Outperform

THOMSON REUTERS
·
Jul 30

Street View: Capricor in 'precarious Position' as Approval in Doubt

Reuters
·
Jul 30

HC Wainwright Downgrades Capricor Therapeutics to Neutral From Buy

MT Newswires Live
·
Jul 30

Capricor Therapeutics Cut to Neutral from Buy by HC Wainwright & Co.

Dow Jones
·
Jul 30

Capricor Therapeutics resumes trading, shares sink 55% to $2.99

TIPRANKS
·
Jul 30

Capricor Therapeutics Shares Down 52% Premarket After FDA Panel Votes Against Co's Duchenne Heart Disease Therapy

THOMSON REUTERS
·
Jul 30

U.S. Research ROUNDUP-Equinix, Meta, S&P Global

Reuters
·
Jul 30

Capricor Therapeutics Inc : Piper Sandler Cuts to Neutral from Overweight; Cuts Target Price to $2 from $58

THOMSON REUTERS
·
Jul 30

FDA panel votes 9-3 against Capricor’s deramiocel

TIPRANKS
·
Jul 30

Capricor downgraded to Neutral from Overweight at Cantor Fitzgerald

TIPRANKS
·
Jul 30

FDA Advisers Vote Against Capricor's Duchenne Heart Disease Therapy

Reuters
·
Jul 30

Capricor Therapeutics (CAPR) Falls On FDA Doubts, Where Does Fair Value Sit?

Simply Wall St.
·
Jul 29

Capricor Therapeutics announces publication of HOPE-3 data on deramiocel

TIPRANKS
·
Jul 29

Capricor Says Phase 3 Hope-3 Trial Shows Deramiocel Slows Upper Limb Decline 54% in Duchenne Muscular Dystrophy

Reuters
·
Jul 29

The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy

GlobeNewswire
·
Jul 29

NASDAQ Trade Halt Halt News Pending at 06:55 Am

Reuters
·
Jul 29